In situ vaccination with Arf1 inhibition was effective not only against melanoma but also against tumors of a variety of histologic types, such as colon cancer (CT26) and breast carcinoma (4T1) (Supplementary Fig. 14a–c). This evidence concerns the gene ARF1 and malignant colon neoplasm.